Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab

Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab

Abstract Objective To assess the efficacy of golimumab (GLM) as a treatment option for juvenile idiopathic arthritis (JIA)-associated uveitis refractory to adalimumab (ADA). Methods Retrospective single-centre study including patients with JIA receiving GLM for active uveitis after failing ADA. JIA-...

Full description

Bibliographic Details
Main Authors: Sofia Lanz, Gerald Seidel, Andrea Skrabl-Baumgartner
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Juvenile idiopathic arthritis
Refractory uveitis
Golimumab
Adalimumab
Treatment failure
Online Access:https://doi.org/10.1186/s12969-021-00630-1

Internet

https://doi.org/10.1186/s12969-021-00630-1

Similar Items